Immunity to varicella zoster virus in young Israeli adults
- PMID: 10774265
Immunity to varicella zoster virus in young Israeli adults
Abstract
Background: Chickenpox is a highly contagious childhood infection caused by varicella zoster virus, a virus of the herpes family. Although a mild and self-limiting disease in otherwise healthy children, chickenpox can be a complicated and even life-threatening disease in adults, pregnant women and immunosuppressed individuals. Among infants whose mothers had varicella during the first trimester of pregnancy, 2-3% will develop a congenital VZV syndrome that includes a combination of scarring, limb deformation, central nervous system impairment and ocular injury. In 1974, a live attenuated virus vaccine against VZV was developed in Japan and has been thoroughly tested for safety, efficacy and long-term effects. In March 1995 the vaccine was licensed in the U.S. for use in healthy children only.
Objectives: To determine the rate of immunity to VZV in young Israeli adults.
Methods: On the assumption that a randomly picked sample of 18-year-old army recruits in Israel is representative of the general Jewish population, 900 sera samples were taken for 3 years (1985,1988,1992). The sera were analyzed for IgG to VZV with a commercial ELISA kit using microwells coated with VZV antigens.
Results: A total of 98% of the samples tested positive for VZV antibodies. The difference in serologic values between the recruitment years was not statistically significant.
Conclusion: The majority of the Israeli population reaches adulthood already immunized against VZV, with immigrants having slightly lower immunity rates. Nonetheless, a few dozen cases of chickenpox are diagnosed in the IDF annually. These data should be taken into account when a vaccination program is devised. Should such a program be implemented, it would be interesting to repeat the serosurvey for comparison. A shift in the peak occurrence age might necessitate the administration of a booster vaccine at an older age.
Comment in
-
Impact of virus infection on adults.Isr Med Assoc J. 2000 Mar;2(3):224. Isr Med Assoc J. 2000. PMID: 10774272 No abstract available.
Similar articles
-
Immunity to varicella zoster virus among young adults: a decline prior to widespread uptake of varicella vaccines.Infection. 2008 Mar;36(2):130-4. doi: 10.1007/s15010-007-7192-7. Epub 2008 Mar 31. Infection. 2008. PMID: 18379727
-
Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age.Vaccine. 2006 Apr 12;24(16):3258-60. doi: 10.1016/j.vaccine.2006.01.026. Epub 2006 Jan 19. Vaccine. 2006. PMID: 16459000
-
Seroprevalence of varicella-zoster virus in Polish population.Przegl Epidemiol. 2009;63(4):495-9. Przegl Epidemiol. 2009. PMID: 20120946
-
[Primary varicella-zoster virus infection--current knowledge, diagnostic and therapeutic approaches].Med Pregl. 2000 May-Jun;53(5-6):272-6. Med Pregl. 2000. PMID: 11089369 Review. Croatian.
-
Prospects for use of a varicella vaccine in adults.Infect Dis Clin North Am. 1990 Mar;4(1):159-73. Infect Dis Clin North Am. 1990. PMID: 2155261 Review.
Cited by
-
A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.Biomedicines. 2022 Aug 22;10(8):2050. doi: 10.3390/biomedicines10082050. Biomedicines. 2022. PMID: 36009598 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources